2015 Volume 4 Issue 4 Pages 91-100
In spite of the remarkable progress in diagnostic technology and the introduction of more effective and less toxic antifungal agents, invasive fungal infections (IFIs) remain one of the most serious complications after hematopoietic stem cell transplantation (HSCT). The accurate evaluation of patient’s immune status and surrounding environment hold important clues to success in the management of post-transplant IFIs, because host factors have become more diversified and complicated by the expanding indications for HSCT. Balance between efficacy and toxicity of antifungal prophylaxis and treatment should be also maintained, by fully understanding the characteristics of each antifungal agent and targeted pathogen, and by assessing patient’s medical conditions over time. Further improvement of clinical outcome will be achieved by optimizing diagnostic, prophylactic and therapeutic approach based on individual patient’s risk and situation. This review summarizes recent advances in the management of IFIs in HSCT recipients.
